Precision BioSciences, Inc.
DTIL
$6.30
$0.6311.11%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5,261.13% | -97.74% | -99.96% | -99.84% | -90.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5,261.13% | -97.74% | -99.96% | -99.84% | -90.93% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 5,261.13% | -97.74% | -99.96% | -99.84% | -90.93% |
| SG&A Expenses | 0.42% | -15.79% | 6.30% | 2.73% | 5.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.86% | -5.36% | -14.98% | 1.70% | 16.22% |
| Operating Income | 150.34% | 2.86% | -190.60% | -428.11% | -66.86% |
| Income Before Tax | 208.47% | -32.55% | -171.82% | -339.46% | -32.09% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 208.47% | -32.55% | -171.82% | -339.46% | -32.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 213.46% | -32.55% | -171.82% | -339.46% | -8.94% |
| EBIT | 150.34% | 2.86% | -190.60% | -428.11% | -66.86% |
| EBITDA | 152.69% | 1.18% | -185.19% | -613.44% | -79.21% |
| EPS Basic | 147.64% | 18.27% | -145.29% | -230.43% | 45.41% |
| Normalized Basic EPS | 148.87% | 21.01% | -144.98% | -224.68% | 42.35% |
| EPS Diluted | 147.31% | 18.27% | -145.61% | -230.43% | 45.35% |
| Normalized Diluted EPS | 148.57% | 21.01% | -145.28% | -224.74% | 42.35% |
| Average Basic Shares Outstanding | 138.16% | 62.18% | 58.56% | 83.60% | 108.24% |
| Average Diluted Shares Outstanding | 139.67% | 62.18% | 57.54% | 83.52% | 108.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |